‘We're seeing profound reversal of a number of conditions’
Вставка
- Опубліковано 5 чер 2024
- Repair Bio is harnessing gene therapy's potential to clear excess cholesterol with a platform that could reshape cardiovascular treatment.
Repair Biotechnologies is developing a novel approach to cholesterol management with its Cholesterol Degrading Platform (CDP); this innovative approach moves beyond conventional cholesterol-lowering strategies, aiming instead to degrade cholesterol at the cellular level.
The Syracuse, New York-based biotech is using unique lipid nanoparticle (LNP)-messenger RNA (mRNA) therapies designed to address the root causes of conditions stemming from localized cholesterol accumulation, setting a new standard in therapeutic interventions.
Unlike traditional methods that merely reduce LDL-cholesterol levels in the bloodstream, Repair Bio’s strategy targets the intracellular free cholesterol that is toxic to cells and a contributing factor in a variety of diseases. This approach not only promises to mitigate atherosclerosis but also shows potential in treating metabolic dysfunction-associated steatohepatitis (MASH), as evidenced by promising results in preclinical mouse models.
Atherosclerosis, marked by the buildup of arterial plaque, significantly impedes blood flow and is a major contributor to cardiovascular disease (CVD) - the leading cause of death worldwide. To address this pressing health burden, scientists at Repair Bio have developed a novel LNP-mRNA therapy, and in recent experiments, atherosclerotic mouse models treated with this therapy over a six-week period demonstrated promising results. It is an innovative approach that not only holds potential for mitigating atherosclerosis but also offers a pathway to reducing the global burden of CVD, ultimately saving lives and improving health outcomes.
The viability of this approach was further underscored when Repair Bio recently received favorable pre-IND feedback from the FDA, marking a significant milestone as the company prepares for clinical trials. We sat down with Reason, the Founder and CEO of Repair Bio, to find out more about the platform, upcoming clinical trials and tackling the Goldilocks problem in delivery systems.
------------------------------
Visit Longevity.Technology - bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter/X - bit.ly/3AMIXuq
Facebook - bit.ly/3z8H1v5
Instagram - bit.ly/3IDvVRX
LinkedIn - bit.ly/3yIfDmf
Find out more about Repair Biotechnologies and its novel platform here -
www.repairbiotechnologies.com/
Very exciting work… I am somewhat in awe and have a lot of respect and admiration for the types of people who have the capacity to innovate and research the science behind this.
Reason really inspires a lot of confidence.
Well, not really, and purely because of his appearance. He would really benefit from a nice shave& haircut Spa.
Very lucid presentation. How about Lp(a)?
This is really interesting.
Amazing technology and a great interview!
Wooooo!
So do we really need to start a petition for people to stop using cholesterol and lipoproteins containing cholesterol interchangebly?
Wish you the best ❤. Time will tell . But your late to the game . Decentralization ❤.
Off-topic. Nothing to do with longevity.
It has everything to do with longevity!
@@joyceatkinson6077 No. It just deals with one small health condition.
@@ClassicalLiberalWarriorcardiovascular disease is hardly one small health condition and it affects numerous conditions not just one, he made that clear in the interview
@@CalumnMcAulay Wrong. He needs to discuss longevity.
@@ClassicalLiberalWarrior wrong? End of conversation dude...if you can't see how curing cardiovascular disease isn't conducive to longevity then its futile talking to you. Do yourself a favour and dont respond.